Three-dimensional view of pharmacology
- PMID: 1530004
Three-dimensional view of pharmacology
Erratum in
- Am J Hosp Pharm 1992 Dec;49(12):2929
Abstract
The relationship between the stereochemistry of drugs and their therapeutic and toxic effects is discussed. Molecular structures that have the same chemical constituents and are related to each other as an object and its nonsuperimposable mirror image are enantiomers. A molecule that has at least one pair of enantiomers is a chiral compound, and a 50:50 mixture of enantiomers is a racemic mixture. The enantiomers of a chiral drug may vary in their interactions with chiral or asymmetric environments such as enzymes and receptors. These variations may lead to differences in pharmacology, pharmacokinetics, therapeutic effect, efficacy, and toxicity. For example, dextropropoxyphene is an analgesic, whereas its mirror image, levopropoxyphene, is an antitussive agent. Enantiomers may have identical efficacy and toxicity. They may have the same therapeutic and toxic effects but differ in the magnitude of these effects; one may possess all the pharmacologic activity and the other may be biologically inactive, or both may be pharmacologically active but have qualitatively different therapeutic and toxic effects. Continued research into the stereochemistry of drugs may lead to the development of newer, safer, and more efficacious drugs and other chemical compounds.
Similar articles
-
[Chiral compounds and their pharmacologic effects].Ceska Slov Farm. 1999 May;48(3):107-12. Ceska Slov Farm. 1999. PMID: 10422348 Review. Slovak.
-
Pharmacologically active compounds in the environment and their chirality.Chem Soc Rev. 2010 Nov;39(11):4466-503. doi: 10.1039/c000408c. Epub 2010 Sep 20. Chem Soc Rev. 2010. PMID: 20852776 Review.
-
Racemic mixtures: harmless or potentially toxic?Am J Hosp Pharm. 1992 Sep;49(9 Suppl 1):S15-8. Am J Hosp Pharm. 1992. PMID: 1530003 Review.
-
Enantiomers: implications and complications in developmental pharmacology.Dev Pharmacol Ther. 1992;18(3-4):131-4. Dev Pharmacol Ther. 1992. PMID: 1306801 Review.
-
Clinical pharmacokinetics: current requirements and future perspectives from a regulatory point of view.Xenobiotica. 1993 Nov;23(11):1159-93. doi: 10.3109/00498259309059432. Xenobiotica. 1993. PMID: 8310705 Review.
Cited by
-
Stereoisomers in Psychiatry: The Case of Escitalopram.Prim Care Companion J Clin Psychiatry. 2002 Feb;4(1):20-24. doi: 10.4088/pcc.v04n0107. Prim Care Companion J Clin Psychiatry. 2002. PMID: 15014731 Free PMC article.
-
Understanding the structural basis of species selective, stereospecific inhibition for Cryptosporidium and human thymidylate synthase.FEBS Lett. 2019 Aug;593(15):2069-2078. doi: 10.1002/1873-3468.13474. Epub 2019 Jun 18. FEBS Lett. 2019. PMID: 31172516 Free PMC article.
-
Stereoselective regulations of P-glycoprotein by ginsenoside Rh2 epimers and the potential mechanisms from the view of pharmacokinetics.PLoS One. 2012;7(4):e35768. doi: 10.1371/journal.pone.0035768. Epub 2012 Apr 18. PLoS One. 2012. PMID: 22530069 Free PMC article.
-
A population analysis of nebulized (R)-albuterol in dogs using a novel mixed gut-lung absorption PK-PD model.Pharm Res. 2000 Oct;17(10):1228-35. doi: 10.1023/a:1026466730347. Pharm Res. 2000. PMID: 11145228
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical